Skip to content
Open access

Clinical performance of a sixth-generation high-sensitivity cardiac troponin T assay compared with standard high-sensitivity troponin T in a real-world cohort

Oct 2026 · European Heart Journal · 0 citations

Abstract

Advances in high-sensitivity cardiac troponin T (hs-cTnT) assay technology have improved the accuracy of detecting and quantifying cardiomyocyte injury in patients with suspected acute coronary syndrome (ACS). However, hs-cTnT concentrations may still be influenced by confounding factors unrelated to myocardial infarction. The novel sixth-generation high-sensitivity troponin T assay (hs-TnT-Gen6) offers enhanced analytical sensitivity and improved tolerance to haemolysis. To evaluate the diagnostic performance and reclassification safety of the hs-cTnT Gen 6 assay in a prospective, unselected real-world cohort. We conducted a prospective observational study including 423 consecutive patients presenting to the emergency department (ED) of a tertiary university hospital in whom current standard hs-cTnT levels were measured. For each patient, a parallel blinded measurement using a hs-cTnT-Gen6 assay was performed in the hospital’s central laboratory. Categorical classification (low vs. high) was defined using a pre-specified threshold of 13 ng/L for standard hs-cTnT and the sex-specific 99th percentile upper reference limits for the Gen6 assay (18 ng/L for females; 32 ng/L for males). All patients were followed until discharge, and final diagnoses were adjudicated. Baseline characteristics of the study population (n = 423; median age 65.0 years [50.0–79.5]; 58.9% male), stratified according to sex-specific 99th percentile thresholds, are summarised in Table 1. A strong correlation was observed between the standard hs-cTnT and hs-cTnT-Gen6 assays (r = 0.98; p < 0.001). Bland–Altman analysis showed minimal differences within the normal range (≤13 ng/L), with deviations generally within ±5 ng/L. Above the 99th percentile, the absolute difference increased with concentration; at 200–400 ng/L, hs-cTnT Gen 6 values exceeded standard hs-cTnT by approximately 180–260 ng/L. Compared with the standard assay, hs-cTnT-Gen 6 reclassified 44 of 423 patients (10.4%): 43 cases (10.2%) were reclassified as normal, whereas only one (0.2%) was reclassified as high (Figure 1). Among the 43 downwardly reclassified patients, who represented 21% of initial high values with standard hs-cTnT, ACS was ruled out in 41 cases (95%), whereas the remaining two patients presented early with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, respectively. The single upwardly reclassified patient had not a final diagnosis of ACS. The categorical Net Reclassification Improvement was −9.9% (95% CI −12.9% to −7.0%). The hs-cTnT Gen 6 assay may improve the precision of troponin-based risk stratification in the emergency department. In particular, it accurately reclassified a substantial proportion of low-risk individuals, which may contribute to more efficient resource utilisation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.